NGNE
Neurogene Inc.
NASDAQ · USHealthcareBiotechnology
$37.34+0.08%
Price as of Jul 20, 2026
NGNE financials
Neurogene Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $925.0K | $0.00 | $0.00 |
| Cost of revenue | $3.2M | $3.2M | $3.3M | $3.2M |
| Gross profit | -$3.2M | -$2.3M | -$3.3M | -$3.2M |
| Operating expenses | $100.0M | $80.3M | $52.3M | $53.3M |
| Operating income | -$103.2M | -$82.6M | -$55.6M | -$56.5M |
| Net income | -$90.4M | -$75.1M | -$36.3M | -$55.2M |
| EBITDA | -$87.3M | -$71.9M | -$33.0M | -$52.0M |
| Basic EPS | $-4.24 | $-4.28 | $-2.83 | $-4.30 |
| Diluted EPS | $-4.24 | $-4.28 | $-2.83 | $-4.30 |
| Balance sheet | ||||
| Cash & equivalents | $103.8M | $136.6M | $148.2M | $82.0M |
| Total assets | $288.6M | $335.7M | $222.6M | $109.3M |
| Total liabilities | $23.7M | $25.4M | $36.5M | $10.6M |
| Stockholders’ equity | $264.9M | $310.4M | $186.0M | $98.6M |
| Total debt | $9.9M | $12.4M | $16.3M | $4.7M |
| Net debt | -$94.0M | -$124.2M | -$132.0M | -$77.3M |
| Cash flow | ||||
| Operating cash flow | -$77.2M | -$70.6M | -$51.4M | -$52.8M |
| Capital expenditure | -$1.2M | -$808.0K | -$321.0K | -$2.2M |
| Free cash flow | -$78.4M | -$71.4M | -$51.7M | -$55.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |